N.V. “announced interim clinical data as of a February 27, 2025 data cutoff from the ongoing phase 2 trial of the bispecific ...

Despite a risk for severe side effects, pembrolizumab has a record of improving recurrence-free survival that makes it an ...

Conference Call on Thursday, May 22 at 5:30 p.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), an ...

Five-year data from the KEYNOTE-048 trial support the use of pembrolizumab and pembrolizumab-chemotherapy as standards of care, researchers wrote.

Merus N.V. (MRUS) stock surges after interim trial data from a cancer trial for the company's lead asset, petosemtamab with ...

From antibody-drug conjugates to PARP inhibitors, innovative treatments are offering new hope for patients with ...

As the oncology community prepares for the 2025 American Society of Clinical Oncology Annual Meeting, anticipation is running ...

The KEYNOTE-B96 study of pembrolizumab plus paclitaxel in recurrent platinum-resistant ovarian cancer has met its primary end point of progression-free survival.

Merus N.V. (NASDAQ: MRUS) shares are trading higher Friday after the company reported promising interim results from its ...

ATG-022 is Antengene's CLDN18.2 antibody-drug conjugate; KEYTRUDA® (pembrolizumab) is MSD's anti-PD-1 therapy.

Bicara Therapeutics Inc. (NASDAQ: BCAX) shares are trading lower Friday following the release of updated interim data.

Teos and GSK were the last to report a new setback in TIGIT targeting for non-small cell lung cancer patients. Read why I am ...